Trial Profile
A Multicentre, Retrospective, Open-label Cohort Study Assessing the Effectiveness and Safety of Ustekinumab in Patients with Refractory Crohn's Disease in Real-Life Setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Ustekinumab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 20 Feb 2018 New trial record